Biodesix

BDSXPhase 3

Biodesix is a data-driven diagnostic company that integrates proteomics, genomics, and artificial intelligence to deliver real-world diagnostic solutions for lung disease. The company has a commercial portfolio of blood-based tests, including the Nodify XL2® and Nodify CDT® tests for lung nodule management, and the GeneStrat® and VeriStrat® tests for therapy selection in NSCLC. Its strategy centers on expanding the clinical utility of its tests, driving adoption, and leveraging its proprietary Biodesix Lung Database® to develop new diagnostic products.

Market Cap

$209.0M

Employees

200-500

Focus

Biotech

BDSX · Stock Price

USD 21.20235.00 (-91.73%)

Historical price data

AI Company Overview

Technology Platform

A proprietary diagnostic platform integrating multi-omics data (proteomics and genomics), artificial intelligence, and machine learning with a real-world clinical database (Biodesix Lung Database®) to discover, develop, and commercialize blood-based tests.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Erlotinib + Docetaxel	Carcinoma, Non-Small-Cell Lung	Phase 3
Ficlatuzumab + Cytarabine	Acute Myeloid Leukemia	Phase 2
Ficlatuzumab + Erlotinib + placebo	Non-small Cell Lung Cancer	Phase 2

Funding History

Total raised: $163M

IPO$85MUndisclosedOct 1, 2020

Series D$15MMerieux Equity PartnersJun 15, 2018

Series C$15MMerieux Equity PartnersJun 15, 2015

Series B$33MMerieux Equity PartnersJun 15, 2013

Opportunities

Significant growth opportunities exist in expanding adoption of its lung nodule tests within the massive LDCT screening population and increasing market share in the competitive liquid biopsy space for NSCLC.

The proprietary Biodesix Lung Database® provides a unique asset to rapidly develop and validate new diagnostic tests for other unmet needs in lung disease and beyond.

Risk Factors

Key risks include dependence on favorable and stable reimbursement from payers, intense competition from larger diagnostic companies, the challenge of driving physician adoption in a crowded market, and the evolving regulatory landscape for laboratory-developed tests (LDTs).

Competitive Landscape

Biodesix competes with large liquid biopsy leaders like Guardant Health and Foundation Medicine in NSCLC genomic testing, and with various companies in the lung nodule assessment space. Its differentiation lies in its integrated multi-omics approach (combining proteomics via VeriStrat with genomics via GeneStrat) and its focus on real-world evidence generated from its proprietary clinical database.